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Abstract
Background: Brugada syndrome (BrS) is an inherited cardiac condition transmitted with 
an autosomal dominant pattern which can lead to sudden cardiac death from malignant 
ventricular arrhythmias. The RANGRF gene has recently been proposed to be associated with 
BrS. This gene encodes the MOG1 protein, a co-factor required for the full functioning of the 
cardiac sodium channel Nav1.5. The nonsense p.E61X genetic variation in the RANGRF gene 
has been postulated as responsible for BrS although no clear association has been established.
Methods: We clinically and genetically evaluated a Spanish family diagnosed with BrS.  
A comprehensive genetic analysis of all genes to date responsible for BrS was performed in  
the index case.
Results: The index case was clinically diagnosed with BrS after flecainide test. We identified 
a nonsense variation (p.E61X) in the index case and in other 5 family members. All of them 
showed a normal electrocardiogram (ECG) in basal conditions. Flecainide test unmasked  
a type 1 BrS ECG only in 2 of the relatives.
Conclusions: We suggest that p.E61X_RANGRF is a rare genetic variation with an uncer-
tain role in BrS. Further studies must be performed to elucidate the potential pathogenic role 
of p.E61X_RANGRF in BrS. (Cardiol J 2014; 21, 2: 121–127)
Key words: sudden cardiac death, Brugada syndrome, RANGRF gene,  
nonsense mutation
Introduction
Brugada syndrome (BrS) is an inherited car-
diac disease characterized by a typical electrocar-
diogram (ECG) pattern of ST segment elevation 
in the right precordial leads (V1–V3) [1]. BrS is 
associated with sudden cardiac death (SCD) by 
polymorphic ventricular tachycardia or ventricular 
fibrillation [2]. The prevalence of the disease is 
believed in the range of 5 to 50 cases per 10,000 
individuals. However, it is difficult to ascertain 
because there is a high percentage of asymptomatic 
patients who remain undiagnosed and with a conce-
aled ECG pattern [3–5]. The average age of onset of 
symptoms is about 30–40 years, although they may 
occur both in childhood and in older age [3, 6]. The 
diagnosis of BrS is based solely on clinical and ECG 
parameters [7], but actual criteria for a conclusive 
diagnosis have been highly debated [8–10].
BrS is a genetic disease [11], so far linked to 
SCN5A, GPD1L, CACNA1C, CACNB2, SCN1B, 
KCNE3, SCN3B, KCNJ8, HCN4, RANGRF, 
KCNE5, KCND3 and CACNA2D1 genes. These 
genes encode proteins that participate directly or 
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indirectly in the generation of the cardiac action 
potential. Around 25% of BrS cases can be attribu-
ted to mutations identified in the SCN5A gene [12], 
which encodes the Nav1.5 protein. All other genes 
together are responsible for an additional 2–5% of 
total BrS cases [13–18]. Debate continues about 
BrS-related role of these minor genes because 
only a few mutations have been identified in few 
families. Therefore, further familiar genetic studies 
are required in additional BrS cohorts in order to 
validate the causative relationship between muta-
tions in the less prevalent genes and BrS.
The RAN guanine nucleotide release factor 
(RANGRF) gene — Chr17p13.1 — has recently 
been associated to BrS. This gene encodes the hu-
man MOG1 protein (Multicopy suppressor of Gsp1) 
[19] (human, Q9HD47 protein). To date, 4 isoforms 
due to alternative splicing (Q9HD47-1, Q9HD47-2, 
Q9HD47-3, Q9HD47-4) have been described; 
to date, Q9HD47-1 is considered the canonical 
sequence. MOG1 protein interacts with Nav1.5 
channel via its intracellular loop between domains 
II and III, and co-localizes with the sodium channel 
at intercalated disks in ventricular myocytes [20]. 
Interestingly, Nav1.5 and MOG1 co-expression 
increases sodium current without changes in the 
channel biophysical properties, suggesting that 
MOG1 protein regulates the expression of Nav1.5 
at the cell surface [21]. To date, only 2 variations 
in the RANGRF gene have been linked to BrS. The 
first described mutation was a missense variation 
(p.E83D) which impairs the trafficking of Nav1.5 
to the membrane. This impairment reduces so-
dium current (INa) and brings the phenotype of 
BrS [14]. However, the BrS phenotype showed by 
the patient carrying this genetic variation is still 
a matter of debate. The second genetic variation, 
p.E61X, was reported in an asymptomatic male 
patient with a type-1 BrS ECG pattern [22]. In 
vitro studies of this genetic variation also showed 
loss of INa function. More recently, this nonsense 
variation was reported in a Danish cohort affected 
by lone atrial fibrillation (AF) [23]. The p.E61X 
genetic variation has therefore been associated 
with an increased risk of arrhythmias. However, 
the presence of this variation in 0.4% of the Da-
nish population [23] has brought into question its 
association with BrS [24].
In the present study, we performed a genoty-
pe-phenotype correlation in a Spanish family affec-
ted by BrS. Genetic screening identified p.E61X 
nonsense genetic variation in the RANGRF gene. 
Our goal was to clarify the potential pathogenic 
role of p.E61X_RANGRF in BrS.
Methods
Clinical study
Nine members of 1 Spanish family were cli-
nically evaluated in Hospital Clinic (Barcelona, 
Spain). Informed consent of all the patients was 
obtained in accordance with the local institutional 
review board guidelines of Hospital Josep Trueta 
(Girona, Spain) and University of Girona (Girona, 
Spain). The diagnosis of BrS was accepted when 
the patients showed an ECG type 1 (basally or after 
the administration of intravenous sodium channel 
blockers) in conjunction with at least 1 clinical 
criterion, reflecting the occurrence of documented 
ventricular arrhythmia, family history (of SCD or 
BrS) and/or symptoms secondary to arrhythmia. 
Structural heart disease was ruled out in all the 
participating individuals.
Genetic analysis
Genomic DNA was extracted from blood 
samples following commercial protocols (PURE-
GENE DNA, QIAGEN). Subsequently, polymerase 
chain reaction (PCR) was used to amplify each 
gene of interest. PCR products were purified 
using ExoSAP-IT (ISOGEN), and the analysis 
of the exonic and intron-exon regions was per-
formed by direct sequencing (Genetic Analyzer 
3130XL, Applied Biosystems). The proband un-
derwent a genetic study of SCN5A (NM000335), 
GPD1L (NM015141), CACNA1C (NM000719), 
CACNB2 (NM000724), SCN1B (NM001037), 
KCNE3 (NM005472), SCN3B (NM018400), 
KCNE5 (NM012282), KCND3 (NM004980.4), 
KCNJ8 (NM004982), HCN4 (NM005477), CAC-
NA2D1 (NM000722) and RANGRF (NM016492) 
genes (NCBI, National Center for Biotechnology 
Information, http://www.ncbi.nlm.nih.gov/). For 
each new genetic alteration identified, a genetic 
analysis was carried out in 328 Spanish unrelated 
control subjects (656 control alleles), individuals 
not related to any patient and of the same ethnici-
ty. In silico pathogenicity of the genetic variation 
was consulted in CONDEL software (CONsensus 
DELeteriousness score of missense SNVs) (http://
bg.upf.edu/condel/). In addition, allelic frequency 
was consulted in Exome Variant Server (EVS) 
(http://evs.gs.washington.edu/EVS/).
Results
Clinical characteristics
The index case (II.3) was a 42-year-old male 
patient, who presented a type 2 BrS ECG pattern 
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during a routine medical evaluation at work. He 
had no previous history of syncope, seizures 
or nocturnal agonal respiration. He underwent 
a flecainide test, during which he developed a type 1 
BrS pattern (Fig. 1A). Because 2 of his brothers 
(II.2 and II.7) had died suddenly after birth, he un-
derwent electrophysiological study (EPS) for risk 
stratification. During EPS, ventricular fibrillation 
was induced, requiring external defibrillation. He 
received an implantable cardioverter defibrillator. 
None of his relatives showed a diagnostic BrS ECG 
pattern at baseline. Four relatives underwent fle-
cainide test (II.1, II.5, II.6 and III.1). Two showed 
a positive BrS ECG (II.5, II.6) (Fig. 1B). Four family 
members did not undergo the flecainide test (I.1 — 
73 years old, I.2 — 71 years old, II.4 — 40 years 
old, III.2 — 6 years old) (Fig. 2).
Genetic analysis
The index case (II.3) was screened for exons 
and flanking introns of all known BrS-related ge-
nes. A nonsense genetic variation (p.E61X) was 
identified in the RANGRF gene. A DNA sequencing 
Figure 1. A. Twelve-lead electrocardiogram (ECG) of the proband (II.3) after flecainide test. The ECG shows a typical 
Brugada syndrome (BrS) pattern; B. Twelve-lead ECG of proband’s son (III.1) after flecainide test. The ECG shows 
a negative BrS pattern.
A
B
Figure 2. Pedigree. II.3 represents the index case. Squa-
res represent men, circles represent women. Slashes 
represent deceased members. None of the patients 
displayed a diagnostic electrocardiogram type 1 pattern 
at baseline. Letter G with plus signs below circle/squa-
res indicates carriers of the genetic variation p.E61X and 
letter G with minus signs below circle/squares indicates 
non-carriers. Letter F with plus signs below circle/squa-
res indicates positive flecainide test. Letter F with minus 
signs below circle/squares indicates negative flecainide 
test. No letter F below circle/squares indicates no fleca-
inide test performed. 
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analysis revealed a G to T base substitution at 
position 181 (c.181G>T) in exon 2 which caused 
a change from GAA (E, Glu, glutamic acid) to stop 
codon TAA (X, OCH, OCHer) at position 61 (Fig. 3). 
This nonsense variation was previously reported, 
(rs140704891) although with unknown pathogenic 
effect. Three previously described single nucleo-
tide polymorphisms (SNPs) were also identified, 
situated in 3 different genes (p.F66F in exon 2 of 
the KCNE3 gene — rs2270676; p.D600E in exon 
13 of the CACNB2 gene — rs58225473; p.P1883P 
in exon 46 of the CACNA1C gene — rs56270948). 
The genetic evaluation of all family members con-
firmed that 5 of them carried the p.E61X genetic 
variation (I.1, II.5, II.6, III.1, and III.2) (Fig. 2).
Phenotype-genotype correlation
The index case (II.3) showed the BrS ECG 
pattern after flecainide test (Fig. 1) and carried 
the nonsense genetic variation (Fig. 3). Two of his 
brothers (II.5 and II.6) carried the same genetic 
variation, and flecainide test also revealed BrS ECG 
pattern in both of them (Fig. 2). The proband has 
1 son (III.1) and 1 daughter (III.2), both carried 
the nonsense genetic variation. However, his son 
did not show BrS ECG pattern after flecainide test 
(Fig. 1B).
In silico analysis
The EVS database for the listed alleles in 
European-American (EA) showed an allele count 
of T=46/G=8550. Therefore, the minor allele 
frequency (MAF) is 0.535%. The EA genotype 
is TT=0/TG=46/GG=4252. The NCBI database 
showed frequencies of 0.995% for the G allele and 
0.005% for the T allele. Genotype distributions 
showed frequencies of G/G: 0.989%, G/T: 0.011% 
and T/T: 0%. The 1000 genomes database reports 
MAF = 0.2%, in concordance with EVS database.
Evolutionary studies have described 4 diffe-
rent isoforms of human RANGRF (Q9HD47-1, 2, 3 
and 4) produced by alternative splicing of this gene. 
Each isoform has a different protein length (186aa, 
146aa, 165aa and 118aa, respectively) although all 
of them share the first region of 117aa. The varia-
tion p.E61X is situated in the conserved region 
(Table 1). In addition, alignment studies show that 
this is a highly conserved region between different 
species (Table 2).
Discussion
We have performed a phenotype-genotype 
correlation in a Spanish family affected by BrS. 
The index case was clinically diagnosed with BrS 
after flecainide test, and genetic analysis reve-
aled the presence of p.E61X genetic variation in 
the RANGRF gene. This genetic variation was 
previously reported by Kattygnarath et al. [22] in 
an asymptomatic patient with a type-1 BrS ECG. 
This nonsense variation was again reported in 
a Danish cohort of patients with AF [23]. Finally, 
Figure 3. DNA forward sequence of the RANGRF gene. Normal sequence (A) and sequence with the genetic variation 
p.E61X (B). Note the substitution c.181G>T (p.Glu61OCH). The triplet GAA (E, Glu) is substituted by stop codon TAA 
(X, OCH).
A B
Table 1. Alignment of the RANGRF gene iso-
forms in human. Bold E indicates the position  
of conserved amino acid between isoforms.
Aminoacid sequence Gene Isoform
ELLELQAHVRGEAAARYHFED Q9HD47
ELLELQAHVRGEAAARYHFED Q9HD47-2
ELLELQAHVRGEAAARYHFED Q9HD47-3
ELLELQAHVRGEAAARYHFED Q9HD47-4
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EPS studies in heterologous systems have shown 
that p.E61X abolishes Nav1.5 current [23]. All 
these data suggest a possible pathological causative 
role of this variation. However, it has been argued 
that the evidence provided in the BrS report is not 
sufficient for a conclusive diagnosis of BrS [24]. In 
addition, the variation has been identified in 0.4% 
of healthy individuals [23]. These have added to 
the ambiguity of the role of p.E61X_RANGRF in 
arrhythmogenesis. This phenomenon also occurs 
in other genetic variants of unknown significance 
(GVUS) because of recent exome studies in BrS 
cohorts suggesting no pathogenic role of several 
GVUS, previously associated with BrS [25]. This 
study suggests that exome data should be used as 
a tool in order to predict the pathogenicity of GVUS 
in patients suspected of BrS.
It was reported that different genetic mecha-
nisms may explain the SCD cases [26]. Firstly, 
allelic imbalance has been identified in several 
human genes [27, 28], such as SCN5A [29]. Thus, 
we cannot exclude that allelic expression imbalan-
ce involves a specific splice variant in our family, 
in concordance with Olesen et al. [24], who have 
recently suggested that the allelic imbalance could 
explain phenotype variability in p.E61X_RANGRF 
carriers. Therefore, one limitation of our study 
stems from the alternative splicing of RANGRF 
mRNA. Another mechanism responsible for inhe-
rited channelopathies is copy number variations, 
defined as a DNA segment of 1 kilobase (kb) or 
larger which is present at a variable copy number 
in comparison to a reference genome, and that 
could cause a disease [30]. Thus, a recent study 
has identified a large-scale rearrangement of the 
SCN5A gene supporting the association between 
the molecular pathology and the phenotypic ex-
pression in BrS [31]. Finally, the read-through 
mechanism could explain the phenotype variability 
in our family. It has also been suggested that po-
tential damages from nonsense genetic variations 
may be reduced or even avoided to a tolerable level 
by translational read-through. This mechanism 
enables ribosomes to ignore the stop codon and 
produce full-length proteins. For instance, Teng et 
al. [32] reported the read-through of a nonsense 
mutation (p.W822X_SCN5A) that restored sodium 
channel expression.
In the present study we identified the genetic 
variation p.E61X_RANGRF in the index case and 
in 5 of his relatives. It is generally accepted that 
nonsense mutations, which lead to synthesis of 
a truncated proteins, should induce a severe effect in 
phenotype. In the case we are discussing, p.E61X_ 
_RANGRF genetic variation induces a premature 
“stop codon” that truncates the protein upstream 
of the region that interacts with Nav1.5 [20]. Since 
protein MOG1 was described as a co-factor for 
optimal expression of Nav1.5 at cell membrane 
[21], p.E61X_RANGRF would potentially cause 
a disruption in Nav1.5 trafficking. In our study, none 
of the 6 family members that carried the genetic 
variation showed any symptoms or a BrS ECG 
pattern at baseline. However, 2 members of the 
family died suddenly at early ages as the first and 
only manifestation of BrS, not infrequent in BrS 
families [33]. Unfortunately, we could not perform 
a genetic study in these deceased relatives. In the 
remaining relatives, flecainide test was performed 
to unmask a BrS phenotype. After flecainide test, 
3 additional family members showed a BrS ECG 
pattern type 1, and all of them carried the genetic 
nonsense variation. The 5th family member, who 
carried the genetic variation, showed a negative 
flecainide test. The reason for that false negative 
result is not well explained in clinical practice, 
but it is well known that flecainide test does not 
unmask all BrS patients who carry a pathogenic 
mutation [34].
All these facts mentioned above are in accor-
dance with incomplete penetrance and variable 
expressivity, hallmarks of BrS [35, 36]. Several 
reasons have been suggested to explain both fe-
atures in BrS, including gender, age and genetic 
factors [37]. The majority of affected patients in 
our family are males. The high proportion of males 
Table 2. Multiple sequence alignment. Conser-
vation of the altered amino acid in the genetic 
variation p.E61X. Bold E indicates the position  
of conserved amino acid between species.
Aminoacid sequence Specie
ELLELQAHVRGEAAARYHFED H. sapiens
ELLELQAHVRGEAAARYHFED C. lupus
ELLELQAHVRGEAAARYHFED B. taurus
ELLELQAHVRGEAAARYHFED R. norvegicus
ELLELQAHVRGEAAARYHFED Mus musculus
ELLELQAQVRGEAAARYHFED Equus  
caballus
ELLELQAHVQGEAAARYHFED Canis  
familiaris
ELLELQAHVRGEAAARYHFED Oryctolagus  
cuniculus
ELLELQAHVRGEAAARYHFED Gorilla gorilla  
gorilla
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among BrS individuals suggests that male hormo-
nes may play a significant role in the phenotype. 
In addition, the average age of presentation of 
symptoms is approximately 40 years. Thus, com-
prehensive hormone studies could be performed in 
all family members to assess their role depending 
on gender and age. In addition, the disease could 
be related with epigenetic factors such as DNA 
methylation, post-translational modifications and 
RNA mechanisms [38, 39]. Finally, a combination 
of 2 or more genetic variations could be required 
to cause BrS phenotype in our family. Although we 
did not identify any other genetic variation, besides 
SNPs, in any of the other BrS tested genes, genetic 
variations in unknown genes may be responsible 
for the phenotype variability. While there is a clear 
link between the variation and the phenotype, the 
family is small, and therefore we cannot exclude 
the possibility that this co-segregation is just by 
coincidence. This fact is in concordance with the 
doubtful involvement of RANGRF in BrS, be-
cause the first genetic variant found in this gene 
(p.E83D_RANGRF) was identified in a patient with 
a non-conclusive BrS diagnostic [14, 24].
According to all information mentioned before, 
recent high-throughput genetics studies help to 
clarify the role of GVUS associated with SCD dise-
ases, such as BrS. In addition, familial correlation is 
crucial to determine the potential pathogenicity of 
each one. So, despite recent genotype-phenotype 
studies, comprehensive clinical assessment is still 
the main current way to diagnose BrS patients.
Conclusions
We favor the hypothesis that p.E61X_RANGRF 
is a rare genetic variation associated with 
a mild BrS phenotype. The data suggest that the 
variation affects the sodium current sufficiently 
enough to unmask the BrS ECG under flecainide 
challenge, but not to bring the ECG pattern at 
baseline. Further studies must be performed 
in large BrS cohorts of different ethnic origin 
to elucidate the role of this nonsense genetic 
variation in BrS.
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